Provided by Tiger Trade Technology Pte. Ltd.

Checkmate Pharmaceuticals

10.50
0.0000
Volume:- -
Turnover:668.00K
Market Cap:231.40M
PE:-3.60
High:10.50
Open:10.50
Low:10.50
Close:10.50
52wk High:10.50
52wk Low:2.00
Shares:22.04M
Float Shares:6.52M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9195
EPS(LYR):-2.8407
ROE:-75.44%
ROA:-42.31%
PB:4.21
PE(LYR):-3.70

Loading ...

Company Profile

Company Name:
Checkmate Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.